Tech Company Financing Transactions

Sutro Biopharma Funding Round

Sutro Biopharma, operating out of South San Francisco, raised $36.5 million from Skyline Ventures, Alta Partners and Amgen Ventures.

Transaction Overview

Company Name
Sutro Biopharma
Announced On
11/17/2010
Transaction Type
Venture Equity
Amount
$36,500,000
Round
Series C
Investors

Skyline Ventures (Lead Investor) (Leon Chen)

Alta Partners (David Mack)

Amgen Ventures

Lilly Ventures (Armen Shanafelt)

SV Health Investors (Michael Ross)

Proceeds Purpose
This financing will support the company's ongoing development of novel biotherapeutics with superior pharmaceutical properties and advance the company's biochemical protein synthesis platform to meet current Good Manufacturing Practice (cGMP) standards.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
310 Utah Ave. 150
South San Francisco, CA 94080
USA
Phone
(650) 392-8412
Website
www.sutrobio.com
Email Address
[email protected]
Overview
Sutro Biopharma, Inc. is a biopharmaceutical company that uses its patented OCFS protein synthesis technology to develop next-generation protein therapeutics for the treatment of human disease.
Profile
Sutro Biopharma LinkedIn Company Profile
Social Media
Sutro Biopharma Company Twitter Account
Company News
Sutro Biopharma News
Facebook
Sutro Biopharma on Facebook
YouTube
Sutro Biopharma on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
William Newell
  William Newell LinkedIn Profile  William Newell Twitter Account  William Newell News  William Newell on Facebook
Chief Financial Officer
Edward Albini
  Edward Albini LinkedIn Profile  Edward Albini Twitter Account  Edward Albini News  Edward Albini on Facebook
Chief Medical Officer
Arturo Molina
  Arturo Molina LinkedIn Profile  Arturo Molina Twitter Account  Arturo Molina News  Arturo Molina on Facebook
Chief Scientific Officer
Trevor Hallam
  Trevor Hallam LinkedIn Profile  Trevor Hallam Twitter Account  Trevor Hallam News  Trevor Hallam on Facebook
Chief Technical Officer
Shabbir Anik
  Shabbir Anik LinkedIn Profile  Shabbir Anik Twitter Account  Shabbir Anik News  Shabbir Anik on Facebook
Vice President
Robert Kiss
  Robert Kiss LinkedIn Profile  Robert Kiss Twitter Account  Robert Kiss News  Robert Kiss on Facebook
Vice President
Mark Lupher
  Mark Lupher LinkedIn Profile  Mark Lupher Twitter Account  Mark Lupher News  Mark Lupher on Facebook
VP - Engineering
Henry Heinsohn
  Henry Heinsohn LinkedIn Profile  Henry Heinsohn Twitter Account  Henry Heinsohn News  Henry Heinsohn on Facebook
VP - Human Resources
Linda Fitzpatrick
  Linda Fitzpatrick LinkedIn Profile  Linda Fitzpatrick Twitter Account  Linda Fitzpatrick News  Linda Fitzpatrick on Facebook
VP - Operations
Nicki Vasquez
  Nicki Vasquez LinkedIn Profile  Nicki Vasquez Twitter Account  Nicki Vasquez News  Nicki Vasquez on Facebook

 

 

Browse more venture capital transactions:

Prev: 11/17/2010: Minerva Biotechnologies venture capital transaction
Next: 11/17/2010: Visage Mobile venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on every notable VC transaction. VC transactions reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.